You just read:

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans

News provided by

Eiger BioPharmaceuticals, Inc.

Feb 04, 2019, 08:00 ET